Research progress on the epidemiology, diagnosis and treatment of JC polyomavirus

doi:10.3877/cma.j.issn.1674-1358.2026.02.004

Abstract

Abstract:

JC polyomavirus (JCPyV) is a widely distributed DNA virus in the human population, typically remaining latent in immunocompetent hosts. When the immune function of the host is compromised, JCPyV can be reactivated and cause progressive multifocal leukoencephalopathy (PML), a severe central nervous system demyelinating disease. This review summarizes the global epidemiological characteristics, molecular biological properties, pathogenesis and related disease research progress of JCPyV, and discusses current diagnostic methods, therapeutic strategies and future research directions, providing theoretical references for the prevention and treatment of JCPyV-associated diseases.

Key words: JC polyomavirus, Progressive multifocal leukoencephalopathy, Epidemiology, Molecular biology, Diagnosis, Treatment

Yulin Zhang, Yong Xiong. Research progress on the epidemiology, diagnosis and treatment of JC polyomavirus[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2026, 20(02): 93-97.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2026.02.004

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2026/V20/I02/93

References 54

[1]	Padgett BL, Walker DL, Zurhein GM, et al. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy[J]. Lancet,1971,1(7712):1257-1260.
[2]	Kartau M, Sipilä JO, Auvinen E, et al. Progressive multifocal leukoencephalopathy: current insights[J]. Degener Neurol Neuromuscul Dis,2019,9:109-121.
[3]	Egli A, Infanti L, Dumoulin A, et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors[J]. J Infect Dis,2009,199(6):837-846.
[4]	Hussain I, Tasneem F, Gilani US, et al. Human BK and JC polyomaviruses: molecular insights and prevalence in Asia[J]. Virus Res,2020,278:197860.
[5]	Kean JM, Rao S, Wang M, et al. Seroepidemiology of human polyomaviruses[J]. PLoS Pathog,2009,5(3):e1000363.
[6]	胡彩琴. HIV-1感染者BK和JC多瘤病毒分子流行病学研究[D]. 浙江: 浙江大学,2019:11-43.
[7]	Lim E, Kamminga S, van der Meijden EE, et al. Seroprevalence of fourteen human polyomaviruses determined in blood donors[J]. PLoS One,2018,13(10):e0206273.
[8]	Hirsch HH, Kardas P, Kranz D, et al. The human JC polyomavirus (JCPyV): virological background and clinical implications[J]. Apmis,2013,121(8):685-727.
[9]	Vanchiere JA, Abudayyeh S, Copeland CM, et al. Polyomavirus shedding in the stool of healthy adults[J]. J Clin Microbiol,2009,47(8):2388-2391.
[10]	Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies[J]. Annu Rev Med,2010,61:35-47.
[11]	Butic AB, Spencer SA, Shaheen SK, et al. Polyomavirus wakes up and chooses neurovirulence[J]. Viruses,2023,15(10):2112.
[12]	中华医学会感染病学分会艾滋病学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南(2024版)[J]. 中华临床感染病杂志,2024,17(3):161-190.
[13]	张甲由. 肾移植术后患者BK/JC病毒感染及与肾功能的相关性研究[D]. 青岛: 青岛大学,2023.
[14]	欧铜, 汤花梅, 崔香蕊, 等. JC多瘤病毒的生物学特征及其感染与肿瘤相关性的研究动态 [J]. 医学综述,2017,23(23):4622-4626.
[15]	Cortese I, Reich DS, Nath A. Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease [J]. Nat Rev Neurol,2020,17(1):37-51.
[16]	Zheng HY, Takasaka T, Noda K, et al. New sequence polymorphisms in the outer loops of the JC polyomavirus major capsid protein (VP1) possibly associated with progressive multifocal leukoencephalopathy[J]. J Gen Virol,2005,86(7):2035-2045.
[17]	Chapagain ML, Verma S, Mercier F, et al. Polyomavirus JC infects human brain microvascular endothelial cells independent of serotonin receptor 2A[J]. Virology,2007,364(1):55-63.
[18]	Wollebo HS, White MK, Gordon J, et al. Persistence and pathogenesis of the neurotropic polyomavirus JC[J]. Ann Neurol,2015,77(4):560-570.
[19]	Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis[J]. Lancet Neurol,2010,9(4):425-437.
[20]	Selgrad M, De Giorgio R, Fini L, et al. JC virus infects the enteric glia of patients with chronic idiopathic intestinal pseudo-obstruction[J]. Gut,2008,58(1):25-32.
[21]	Corey S, Smith BR, Cortese ICM. Promise and challenges of checkpoint inhibitor therapy for Progressive Multifocal Leukoencephalopathy in HIV[J]. Curr HIV/AIDS Rep,2022,19(6):580591.
[22]	Maas RP, Muller-hansma AH, Esselink RA, et al. Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases[J]. J Neurol,2016,263(10):2004-2021.
[23]	何香溪, 甘霖, 符燕华, 等. 15例艾滋病相关进行性多灶性白质脑病临床特点分析 [J]. 传染病信息,2023,36(2):114-118.
[24]	Sainz-de-la-Maza S, Casado JL, Pérez-Elías MJ, et al. Incidence and prognosis of immune reconstitution inflammatory syndrome in HIV‐associated progressive multifocal leucoencephalopathy[J]. Eur J Neurol,2016,23(5):919-925.
[25]	Bauer J, Gold R, Adams O, et al. Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS)[J]. Acta Neuropathologica,2015,130(6):751-764.
[26]	Moulignier A, Lecler A. Neurological complications of JC virus infection: A review[J]. Rev Med Interne,2021,42(3):177-185.
[27]	闫俊, 王梦嫣, 张忠东, 等. HIV感染者尿JC多瘤病毒与肾功能关系5年随访分析[J]. 医学研究杂志,2024,53(6):84-88.
[28]	Delbue S, Comar M, Ferrante P. Review on the role of the human polyomavirus JC in the development of tumors[J]. Infect Agents Cancer,2017,12(1):12-10.
[29]	郑玉双, 郑华川. JC病毒与肿瘤的研究进展[J]. 中华肿瘤防治杂志,2012,19(16):1276-1280.
[30]	Schweitzer L, Barkati S, Laneuville P, et al. Treatment of progressive multifocal leukoencephalopathy with IL-2 and mirtazapine[J]. J Clin Immunol,2024,44(4):97.
[31]	Shavaleh R, Kamandi M, Feiz Disfani H, et al. Association between JC virus and colorectal cancer: systematic review and meta-analysis[J]. Infect Dis,2019,52(3):152-160.
[32]	Sinagra E, Raimondo D, Gallo E, et al. Could JC virus be linked to chronic idiopathic intestinal pseudo-obstruction?[J]. Clin J Gastroenterol,2019,13(3):377-381.
[33]	Ahye N, Bellizzi A, May D, et al. The Role of the JC virus in central nervous system tumorigenesis[J]. Int J Mol Sci,2020,21(17):6236.
[34]	Berger JR, Aksamit AJ, CliffordL DB, et al. PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section[J]. Neurology,2013,80(15):1430-1438.
[35]	毛元岱, 马萍. 艾滋病合并进行性多灶性脑白质病研究进展[J]. 中国艾滋病性病,2024,30(1):89-93.
[36]	钱娟, 黄锐, 曹齐, 等. mNGS技术诊断11例人类免疫缺陷病毒相关进行性多灶性白质脑病及其临床特征[J]. 中国神经精神疾病杂志,2022,48(11):657-663.
[37]	李倩, 邓莉平, 陈果, 等. 宏基因组二代测序在获得性免疫缺陷综合征合并中枢神经系统感染中的临床应用[J/OL]. 中华实验和临床感染病杂志(电子版),2023,17(1):24-31.
[38]	Gu W, Miller S, Chiu CY. Clinical metagenomic next-generation sequencing for pathogen detection[J]. Annu Rev Pathol,2019,14:319-338.
[39]	Wilson MR, Sample HA, Zorn KC, et al. Clinical metagenomic sequencing for diagnosis of meningitis and encephalitis[J]. N Engl J Med,2019,380(24):2327-2340.
[40]	Miller S, Chiu C. The role of metagenomics and next-generation sequencing in infectious disease diagnosis[J]. Clin Chem,2021,68(1):115-124.
[41]	Tavazzi E, Ferrante P, Khalili K. Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies[J]. Clin Microbiol Infect,2011,17(12):1776-1780.
[42]	Gosert R, Rinaldo CH, Wernli M, et al. CMX001 (1-O-hexadecyloxypropyl-cidofovir) inhibits polyomavirus JC replication in human brain progenitor-derived astrocytes[J]. Antimicrob Agents Chemother,2011,55(5):2129-2136.
[43]	Pavlovic D, Pateraa C, Nyberg F, et al. Progressive multifocal leukoencephalopathy: current treatment options and future perspectives[J]. Ther Adv Neurol Disord,2015,8(6):255-273.
[44]	Kast RE, Focosi D, Petrini M, et al. Treatment schedules for 5-HT2A blocking in progressive multifocal leukoencephalopathy using risperidone or ziprasidone[J]. Bone Marrow Transplant,2007,39(12):811-812.
[45]	Royal W 3rd, Dupont B, Mcguire D, et al. Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy[J]. J Neurovirol,2003,9(3):411-419.
[46]	Tan CS, Bord E, Broge TA, et al. Increased program cell death–1 expression on T lymphocytes of patients with progressive multifocal leukoencephalopathy[J]. J Acquir Immune Defic Syndr,2012,60(3):244-248.
[47]	Cortese I, Muranski P, Enose-Akahata Y, et al. Pembrolizumab treatment for progressive multifocal leukoencephalopathy[J]. N Engl J Med,2019,380(17):1597-1605.
[48]	Grote-Levi L, Möhn N, Bonifacius A, et al. Adoptive allogeneic T-Cell therapy improves the clinical outcome of JC virus granule cell neuronopathy[J]. Neurol Neuroimmunol Neuroinflamm,2023,10(5):e200138.
[49]	Balduzzi A, Lucchini G, Hirsch HH, et al. Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient[J]. Bone Marrow Transplant,2011,46(7):987-992.
[50]	Muftuoglu M, Olson A, Marin D, et al. Allogeneic BK virus–specific T cells for progressive multifocal leukoencephalopathy[J]. N Engl J Med,2018,379(15):1443-1451.
[51]	Dunham SR, Schmidt R, Clifford DB. Treatment of progressive multifocal leukoencephalopathy using immune restoration[J]. Neurotherapeutics,2020,17(3):955965.
[52]	李骜航, 杜小莉. 进行性多灶性白质脑病治疗进展[J]. 临床药物治疗杂志,2025,23(2):1-4.
[53]	Pinto M, Dobson S. BK and JC virus: a review[J]. J Infect,2014,68(Suppl 1):S2-S8.
[54]	Sandberg AL, Bond ACS, Bennett LJ, et al. GPCR Inhibitors have antiviral properties against JC polyomavirus Infection[J]. Viruses,2024,16(10):1559.

Please choose a citation manager

Content to export